Literature DB >> 12213056

Synthesis and molecular modeling of new 1-aryl-3-[4-arylpiperazin-1-yl]-1-propane derivatives with high affinity at the serotonin transporter and at 5-HT(1A) receptors.

Lara Orús1, Silvia Pérez-Silanes, Ana-M Oficialdegui, Javier Martínez-Esparza, Juan-C Del Castillo, Marisa Mourelle, Thierry Langer, Salvatore Guccione, Giuseppina Donzella, Eva M Krovat, Konstantin Poptodorov, Berta Lasheras, Santiago Ballaz, Isabel Hervías, Rosa Tordera, Joaquín Del Río, Antonio Monge.   

Abstract

It has been proposed that 5-HT(1A) receptor antagonists augment the antidepressant efficacy of selective serotonin (5-HT) reuptake inhibitors. In a search toward new and efficient antidepressants, 1-(aryl)-3-[4-arylpiperazin-1-yl]-1-propane molecular hybrids were designed, synthesized, and evaluated for 5-HT reuptake inhibition and 5-HT(1A) receptor affinity. The design was based in coupling structural moieties related to inhibition of serotonin reuptake, such as benzo[b]thiophene derivatives to arylpiperazines, typical 5-HT(1A) receptor ligands. In binding studies, several compounds showed affinity at the 5-HT transporter and at 5-HT(1A) receptors. Molecular modeling studies predicted the pharmacophore elements required for high affinity binding and the features that enable to discriminate between agonist, partial agonist, or antagonist action at 5-HT(1A) receptors and 5-HT transporter inhibition. Solvent interactions in desolvation prior to the binding step along with enthalpy and enthropy compensations might be responsible to explain agonist, partial agonist, and antagonist character. Hydrogen-bonding capability seems to be important to break hydrogen interhelical hydrogen bonds or alternatively to form other bonds upon ligand binding. Partial agonists and antagonists are unable to do this as the full agonist, which interacts closely by long-range forces or directly. The compounds showing the higher affinity at both the 5-HT transporter (K(i) < 50 nM) and the 5-HT(1A) receptors (K(i) < 20 nM) were further explored for their ability to stimulate [(35)S]GTPgammaS binding or to antagonize 8-hydroxy-2-di-n-propylamino-tetralin (8-OH-DPAT)-stimulated [(35)]GTPgammaS binding to rat hippocampal membranes, an index of agonist/antagonist action at 5-HT(1A) receptors, respectively. Compound 8g exhibited agonist activity (EC(50) = 30 nM) in this assay, whereas compounds 7g and 8h,i behaved as weak partial agonists and 7h-j and 8j,l antagonized the R(+)-8-OH-DPAT-stimulated GTPgammaS binding. Functional characterization was performed by measuring the antagonism to 8-OH-DPAT-induced hypothermia in mice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12213056     DOI: 10.1021/jm0111200

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Molecular mechanism of serotonin transporter inhibition elucidated by a new flexible docking protocol.

Authors:  Mari Gabrielsen; Rafał Kurczab; Aina W Ravna; Irina Kufareva; Ruben Abagyan; Zdzisław Chilmonczyk; Andrzej J Bojarski; Ingebrigt Sylte
Journal:  Eur J Med Chem       Date:  2011-10-20       Impact factor: 6.514

2.  Discovery of novel selective serotonin reuptake inhibitors through development of a protein-based pharmacophore.

Authors:  Sankar Manepalli; Laura M Geffert; Christopher K Surratt; Jeffry D Madura
Journal:  J Chem Inf Model       Date:  2011-09-02       Impact factor: 4.956

3.  From Homology Models to a Set of Predictive Binding Pockets-a 5-HT1A Receptor Case Study.

Authors:  Dawid Warszycki; Manuel Rueda; Stefan Mordalski; Kurt Kristiansen; Grzegorz Satała; Krzysztof Rataj; Zdzisław Chilmonczyk; Ingebrigt Sylte; Ruben Abagyan; Andrzej J Bojarski
Journal:  J Chem Inf Model       Date:  2017-01-18       Impact factor: 4.956

Review 4.  Trends in the development of new antidepressants. Is there a light at the end of the tunnel?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Med Chem       Date:  2004-04       Impact factor: 4.530

5.  Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models.

Authors:  Balaram Ghosh; Tamara Antonio; Juan Zhen; Prashant Kharkar; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

6.  Synthesis, docking studies and biological evaluation of benzo[b]thiophen-2-yl-3-(4-arylpiperazin-1-yl)-propan-1-one derivatives on 5-HT1A serotonin receptors.

Authors:  Hernán Pessoa-Mahana; Gonzalo Recabarren-Gajardo; Jenny Fiedler Temer; Gerald Zapata-Torres; C David Pessoa-Mahana; Claudio Saitz Barría; Ramiro Araya-Maturana
Journal:  Molecules       Date:  2012-02-03       Impact factor: 4.411

7.  A linear combination of pharmacophore hypotheses as a new tool in search of new active compounds--an application for 5-HT1A receptor ligands.

Authors:  Dawid Warszycki; Stefan Mordalski; Kurt Kristiansen; Rafał Kafel; Ingebrigt Sylte; Zdzisław Chilmonczyk; Andrzej J Bojarski
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

8.  New 1-aryl-3-substituted propanol derivatives as antimalarial agents.

Authors:  Silvia Pérez-Silanes; Luis Berrade; Rory N García-Sánchez; Adela Mendoza; Silvia Galiano; Berta Martín Pérez-Solórzano; Juan J Nogal-Ruiz; Antonio R Martínez-Fernández; Ignacio Aldana; Antonio Monge
Journal:  Molecules       Date:  2009-10-14       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.